Danaher Corporation (NYSE:DHR) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 17, Danaher Corporation (NYSE:DHR) announced an agreement to acquire Masimo ...

Danaher Corporation, a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation a leading specialty diagnostics provider ...

Irvine medical device maker Masimo has entered an agreement to be acquired by Danaher, owner of Brea-based Beckman Coulter, in a $9.9 billion deal.

SMSbiotech, a clinical-stage regenerative medicine company advancing novel cell-based therapies, today announced the appointment of Joe Kiani as Chairman of the Board of Directors. An early supporter ...

The top S&P 500 healthcare gainers and losers for the last week are as follows: Moderna ( MRNA) +24.33% Molina Healthcare ( MOH) +19.17% Baxter International ( BAX) +15.34% ...

The move reflects a broader industry shift toward consolidation and integrated care, as large healthcare companies seek scale ...

Diagnostics business unit News of the agreement sent Masimo’s Nasdaq-listed stock price up in value by more than 30 per cent, with the $180-per-share purchase price last achieved just under a year ago ...

In a column for Investing Club members, Jim Cramer writes that the dramatic multiple compression across the market is making investors' lives difficult.

Irvine-based Tarsus Pharmaceuticals names former Allergan CEO David Pyott to its board of directors as the biotech prepares to report quarterly earnings.

Danaher's acquisition of Masimo shows promising financial upside and long-term growth potential with conservative projections ...

In this week’s edition of InnovationRx, we look at Jennifer Doudna’s $1 billion plan to bring Crispr gene editing to the real ...

Danaher Corp. is snapping up patient monitoring medtech Masimo in a $9.9 billion deal aimed at strengthening its diagnostics ...